Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CareDxSTU:1K9 73 Piotroski F-Score is 6 as of Jul. 24, 2026, which is 50% above its 10-year median of 4.00. GuruFocus rates STU:1K9 with a GF Score™ of 73/100 and a GF Value™ of €18.75 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 209 Medical Diagnostics & Research companies, CareDx ranks better than 79.9% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
CareDx has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for CareDx's Piotroski F-Score or its related term are showing as below:
STU:1K9'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 4 Max: 7
Current: 6
During the past 13 years, the highest Piotroski F-Score of CareDx was 7. The lowest was 1. And the median was 4.
CareDx (STU:1K9) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
CareDx Piotroski F-Score Related Terms
CareDx Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for CareDx's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1K9 vs PSNL, OPK, NEO: Piotroski F-Score Comparison
For the Diagnostics & Research subindustry, CareDx's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CareDx Piotroski F-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, CareDx's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where CareDx's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
CareDx's current Net Income (TTM) was -7.1.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
CareDx's current ratio of this year was 3.40349365. CareDx's current ratio of last year was 4.10672092.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
CareDx's number of shares in issue this year was 53.13. CareDx's number of shares in issue last year was 55.262.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
CareDx's gross margin of this year was 0.68886603. CareDx's gross margin of last year was 0.67624402.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
CareDx's asset turnover of this year was 0.78330371. CareDx's asset turnover of last year was 0.77224216.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
1
+
0
+
1
+
1
+
0
+
1
+
1
+
1
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
CareDx has an F-score of 6 indicating the company's financial situation is typical for a stable company.
CareDx (STU:1K9) has a Piotroski F-Score of 6 as of Jul. 24, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on CareDx and its competitors. This is 50% above median its historical median of 4.00. Over the past decade, CareDx's Piotroski F-Score has ranged from 1.00 to 7.00. According to the industry distribution chart, CareDx ranks #42 out of 209 companies in the Medical Diagnostics & Research industry, placing it in the top 20.1%.
Is CareDx's Piotroski F-Score too high?
CareDx's current Piotroski F-Score of 6 is 50% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. CareDx's value of 6 is 20% above this industry median. Based on the distribution chart, CareDx ranks #42 out of 209 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, CareDx has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CareDx's Piotroski F-Score compare to PSNL and OPK?
According to the Medical Diagnostics & Research industry distribution chart, CareDx ranks #42 out of 209 companies for Piotroski F-Score. This places CareDx in the top 20% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. CareDx's value of 6 is 20% above this benchmark. Historically, CareDx's own Piotroski F-Score has ranged from 1.00 to 7.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, CareDx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 209 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CareDx's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on CareDx and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CareDx's current Piotroski F-Score is 6, which is 50% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CareDx stock overvalued right now?
Based on GuruFocus' analysis, CareDx (STU:1K9) is currently considered Significantly Overvalued. The stock's GF Value™ is €18.75, compared to a current price of €33.00 — trading 76% above its estimated fair value. The current Piotroski F-Score is 6, which is 50% above median its 10-year median of 4.00 and 20% above the Medical Diagnostics & Research industry median of 5.00. CareDx's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For CareDx (STU:1K9), the current Piotroski F-Score is 6 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CareDx (STU:1K9) Overvalued in 2026?
Based on GuruFocus' analysis, CareDx stock appears to be overvalued.
The current stock price of €33.00 is trading 76% above its estimated GF Value™ of €18.75.
GuruFocus considers CareDx to be Significantly Overvalued.
Key valuation signals for STU:1K9:
Piotroski F-Score: 6 (50% above median its 10-year median of 4.00)
GF Value™: €18.75 vs. price of €33.00 (76% above fair value)
Industry Position: 20% above the Medical Diagnostics & Research median (#42 of 209)
No single metric tells the full story. See the STU:1K9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
73GF Score
Get the complete analysis for STU:1K9
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1K9 has been successfully added to your 
